Aprepitant in Preventing Nausea and Vomiting in Patients Undergoing Chemotherapy and Radiation Therapy for Pancreatic Cancer

• Status: Completed
• Trial end date: 2012-08-01

Summary

This pilot clinical trial is studying how well aprepitant works in preventing nausea and vomiting in patients undergoing chemotherapy and radiation therapy for pancreatic cancer. Antiemetic drugs, such as aprepitant may help lessen or prevent nausea and vomiting in patients receiving chemotherapy and radiation therapy

• Phase: Phase 2

Details

• Lead Sponsor: Wake Forest University Health Sciences
• Collaborators: Merck Sharp & Dohme Corp.; National Cancer Institute (NCI)
• Treatments: Antiemetics; Aprepitant; Capecitabine; Fluorouracil; Fosaprepitant; Gemcitabine